Caribou Biosciences Inc (NASDAQ: CRBU) is pleased to present more details about its ANTLER Phase 1 trial. This trail targeted the evaluation of CB-010 to develop and deliver working solutions for patients struggling with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). The company unveils the additional initial clinical data emanating from the trial, and it is happy about the response.
The trial and the findings
The initial dose level of CB-010 involved the administration of a single dose, and the scientists noted the results. Then, the scientists undertook a trial involving 6 patients and obtained a 100% complete response (CR) rate. It found the outcome rather inspiring and described it as the best response.
The administration of a single dose of CB-010 after 6 months provided crucial outcomes for the trial. Scientists reported that 2 of 5 patients remained in CR. The figure translated into percentage stands at 40%, and the results are as of May 13, 2022 data cutoff date.
Loretta’s perspective
The European Hematology Association (EHA) 2022 Hybrid Congress took place in Vienna, Austria. The unveiling of the trial’s data is one of the many presentations at the event. In addition, the associate professor working with the Division of Cancer Medicine at The University of Texas, Loretta J. Nastoupil, has commented on the latest developments.
He describes the preliminary safety and efficacy results as pretty inspirational at such a time when many patients need help. Next, Loretta speaks out about the study involving the six patients subjected to CB-010 at the initial dose level of 40 million CAR-T cells and what that implies. He believes the complete response to be an encouraging factor and speaks out on the other plans that the company has underway.
Caribou Biosciences targets the enrollment of dose level 2, and Loretta exudes confidence in the study, outlining that it is fated to mature. He says that the trail inspired hope with most of its aspects. The most important was how the adverse events were in sync with the various allogeneic or autologous CAR-T cell therapies.
He also talked about the product and its tolerance levels. However, it tells a lot about the positive progress they continue making towards developing working solutions for patients.
